#USA #Nashville #OneOncology #Oncology Quality Hub #CMS Approval

OneOncology Achieves CMS Approval for 2026

In an impactful announcement, OneOncology, a leading national platform aimed at empowering independent medical specialty practices, has received approval from the Centers for Medicare & Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) for the year 2026. This marks the second year in a row that OneOncology has earned this prestigious designation, underscoring its commitment to excellence in the field of oncology.

The approval signifies OneOncology's capability to comply with rigorous federal standards for the collection and submission of clinical data on behalf of healthcare providers participating in CMS's Quality Payment Program. Dr. Davey Daniel, Chief Medical Officer at OneOncology, expressed pride in the achievement, stating, "As a CMS-approved registry for the second year in a row, OneOncology is proud to support our partner practices in achieving strong MIPS performance and meeting program compliance requirements."

Over the past year, OneOncology has expanded its support mechanisms to simplify the reporting process, significantly reduce the administrative burdens faced by practices, and align quality measures with the actual workflows of oncology practices. This effort reflects OneOncology's dedication to enhancing the quality of patient care.

As a QCDR, OneOncology possesses the authority to gather clinical data from various sources and report MIPS measures for its partner practices and clinicians across multiple electronic medical record (EMR) platforms. This capability streamlines quality reporting, promotes improved performance, and ultimately benefits patients by facilitating a higher standard of care.

A notable development from OneOncology is the introduction of a new oncology-specific quality measure that has also received CMS approval for use in the Merit-based Incentive Payment System (MIPS) program. The measure, known as DPYD (dihydropyrimidine dehydrogenase) screening, involves a straightforward genetic test that identifies patients at risk for severe side effects from certain chemotherapy drugs. This advancement allows care teams to tailor treatment plans carefully, reinforcing patient safety.

The DPYD guideline was updated recently by the U.S. Food and Drug Administration and the National Comprehensive Cancer Network, ensuring that OneOncology remains aligned with the latest advancements and recommendations in cancer care. By swiftly developing and receiving approval for this new quality measure shortly after national guidelines were updated, OneOncology highlights its commitment to patient safety and its responsiveness in adapting to evolving care standards.

Katie Miller, Senior Director of Clinical Quality at OneOncology, elaborated on the organization’s ongoing efforts, stating, "As we work with our practice partners to further integrate medical oncology, radiation oncology, and urology within their practices, we look forward to continue utilizing our expertise to help practices achieve quality measures and deliver high-quality specialty care, with a patient-centered, real-world approach to treatment."

OneOncology was established by community physicians with a focus on improving the quality of life for individuals confronted with cancer and other diseases. The platform aims to support community medical practices in remaining independent while enhancing patient access to quality care, all while managing costs effectively compared to hospital settings.

With over 36 partner practices and approximately 2,300 healthcare providers caring for about 1.5 million patients across over 645 sites nationwide, OneOncology is making significant strides in the oncology field through group purchasing, operational enhancement, practice development, and clinical innovation. The organization invites interested parties to learn more about its mission and initiatives by visiting their website at oneoncology.com or following their updates on LinkedIn.